Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 139Vincristine 105Rituximab 100Doxorubicin 87Etoposide 79Prednisone 69Cytarabine 67Filgrastim 63Specimen Handling 62Methotrexate 60Biopsy 60Magnetic Resonance Spectroscopy 51fludarabine phosphate 50Dexamethasone 47Radiotherapy 43Peripheral Blood Stem Cell Transplantation 35Leucovorin 35Bortezomib 32Prednisolone 28Mercaptopurine 27merphos 24Ifosfamide 24Asparaginase 24Daunorubicin 23Lenalidomide 22ibrutinib 21fludarabine 21Calcium Dobesilate 21pegaspargase 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adjuvants, Immunologic × Lymphoid × Clear all
NCT00024115 2015-04-28

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡